# Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

> **NCT03222674** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shenzhen Geno-Immune Medical Institute** · enrollment: 10 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells

## Key facts

- **NCT ID:** NCT03222674
- **Lead sponsor:** Shenzhen Geno-Immune Medical Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-15
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03222674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03222674, "Multi-CAR T Cell Therapy for Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03222674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*